On Wednesday, Capricor Therapeutics got a positive adjustment to its Relative Strength (RS) Rating, from 90 to 93.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves.
Capricor Therapeutics has risen more than 5% past a 5.48 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% EPS growth last quarter. Revenue increased -100%.
The company earns the No. 162 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
